期刊文献+

Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-Ⅱ colon cancer patients 被引量:7

Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-Ⅱ colon cancer patients
下载PDF
导出
摘要 Background and Objective: Colorectal cancer is one of the most common malignant cancers in the world. Although the clinicopathologic staging is the golden criterion for the prognosis at present, the optimum prognostic criteria for colorectal cancer should be a combination of the clinicopathologic staging and the molecular markers. However, there are currently no molecular markers available for the prognosis of colorectal cancer. Several tumor-suppressor genes associated with colorectal cancer have been mapped at the 18q21-23 region. In this study we detected the frequency of loss of heterozygosity (LOH) at chromosome 18q and investigated the relationship between LOH and clinicopathologic features and its prognostic value for patients with stage Ⅱ colon cancer. Methods: A total of 106 samples of tumor tissues and corresponding normal mucosa from patients with sporadic stage-Ⅱ colon cancer were included in this study. All the samples were formalin-fixed and paraffin-embedded. DNA was extracted from tumor tissues and LOH of D18S474, D18S55, D18S58, D18S61 and D18S64 at chromosome 18q was analyzed using polymerase chain reaction (PCR), polyacrylamide gel-electrophoresis, and DNA sequencing method. Multivariate analysis for association between LOH and prognosis in colon cancer patients was performed with Cox proportional hazards regression model. Results: The median follow-up time was 68 months. For 106 patients, 5-year survival rate was 83.6%, which was associated with age and gross tumor type (P = 0.011 and 0.034, respectively). Among 102 patients who were eligible for LOH information, the overall frequency of LOH is 49.0% (50/102), and that of LOH at 5 microsatellite loci of D18S474, D18S55, D18S58, D18S61, and D18S64 was 30.2% (26/86), 23.4% (18/77), 28.6% (20/70), 35.0% (28/80), and 20.8%(15/72), respectively. The occurrence of LOH was significantly associated with tumor location and histopathologic grade (P = 0.023, 0.016 and 0.005, respectively). LOH was more frequent on the left-side, poorly-differentiated adenocarcinoma, and nonmucinous colon cancers. The occurrence of 18q-LOH was significantly associated with 5-year overall survival rate and disease free survival rate (P = 0.008 and 0.006, respectively). The occurrence of 18q-LOH at the loci of D18S474 and D18S61 was significantly associated with 5-year overall survival rate (P = 0.010 and 0.005, respectively). The multivariate analysis showed that only the occurrence of 18q-LOH was significantly associated with prognosis (P = 0.021). Conclusions: There is a high occurrence of LOH at the loci of 18q. The expression of LOH is significantly associated with tumor location and histopathologic grade. The occurrence of 18q-LOH is an independent poor prognostic factor for the patients with stage-Ⅱ colon cancer. Background and Objective: Colorectal cancer is one of the most common malignant cancers in the world. Although the clinicopathologic staging is the golden criterion for the prognosis at present, the optimum prognostic criteria for colorectal cancer should be a combination of the clinicopathologic staging and the molecular markers. However, there are currently no molecular markers available for the prognosis of colorectal cancer. Several tumor-suppressor genes associated with colorectal cancer have been mapped at the 18q21-23 region. In this study we detected the frequency of loss of heterozygosity (LOH) at chromosome 18q and investigated the relationship between LOH and clinicopathologic features and its prognostic value for patients with stage II colon cancer. Methods: A total of 106 samples of tumor tissues and corresponding normal mucosa from patients with sporadic stage-II colon cancer were included in this study. All the samples were formalin-fixed and paraffin-embedded. DNA was extracted from tumor tissues and LOH of D18S474, D18S55, D18S58, D18S61 and D18S64 at chromosome 18q was analyzed using polymerase chain reaction (PCR), polyacrylamide gel-electrophoresis, and DNA sequencing method. Multivariate analysis for association between LOH and prognosis in colon cancer patients was performed with Cox proportional hazards regression model. Results: The median follow-up time was 68 months. For 106 patients, 5-year survival rate was 83.6%, which was associated with age and gross tumor type (P = 0.011 and 0.034, respectively). Among 102 patients who were eligible for LOH information, the overall frequency of LOH is 49.0% (50/102), and that of LOH at 5 micresatellite loci of D18S474, D18S55, D18S58, D18S61, and D18S64 was 30.2% (26/86), 23.4% (18/77), 28.6% (20/70), 35.0% (28/80), and 20.8%(15/72), respectively. The occurrence of LOH was significantly associated with tumor location and histopathologic grade (P = 0.023, 0.016 and 0.005, respectively). LOH was more frequent on the left-side, poorly-differentiated adenocarcinoma, and nonmucinous colon cancers. The occurrence of 18q-LOH was significantly associated with 5-year overall survival rate and disease free survival rate (P = 0.008 and 0.006, respectively). The occurrence of 18q-LOH at the loci of D18S474 and D18S61 was significantly associated with 5-year overall survival rate (P = 0.010 and 0.005, respectively). The multivariate analysis showed that only the occurrence of 18q- LOH was significantly associated with prognosis (P = 0.021). Conclusions: There is a high occurrence of LOH at the loci of 18q. The expression of LOH is significantly associated with tumor location and histopathologic grade, The occurrence of 18q-LOH is an independent poor prognostic factor for the patients with stage-II colon cancer.
出处 《Chinese Journal of Cancer》 SCIE CAS CSCD 北大核心 2010年第8期761-767,共7页
关键词 大肠癌 染色体 杂合性 预后 患者 相关分析 聚丙烯酰胺凝胶电泳 临床病理 Chromosome 18q, loss of heterozygosity, colon cancer, prognosis
  • 相关文献

参考文献1

二级参考文献37

  • 1Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990: 61:759-767.
  • 2Hamilton SR. Molecular genetics of colorectal carcinoma.Cancer 1992; 70(5 Suppl): 1216-1221.
  • 3Baker SJ, Fearon ER,Nigro JM, Hamilton SR, Preisinger AC,Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y. Chromosome 17 deletions and p53 gene rautations in colorectal carcinomas. Science 1989; 244:217-221.
  • 4Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M.Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363:558-561.
  • 5Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR.Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260:812-816.
  • 6Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M,Jarvinen H, Mecklin JP, de la Chapelle A. Incidence of heredi-tary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Eng J Med 1998; 338:1481-1487.
  • 7Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, Thibodeau SN. Hypermethylation of theh MLH1 promoter in colon cancer with microsatellite instability.Cancer Res 1998; 58:3455-3460.
  • 8Kern SE, Fearon ER, Tersmette KW, Enterline JP, Leppert M,Nakamura Y, White R, Vogelstein B, Hamilton SR. Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 1989; 261:3099-3103.
  • 9Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. Allelotype of colorectal carcinomas. Science 1989; 244:207-211.
  • 10Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.N Eng J Med 2000; 342:69-77.

共引文献1

同被引文献142

  • 1Hai-TaoZheng,Zhi-HaiPeng,Chong-ZhiZhou,Da-PengLi,Zhao-WenWang,Guo-QiangQiu,LinHe.Detailed deletion mapping of loss of heterozygosity on 22q13 in sporadic colorectal cancer[J].World Journal of Gastroenterology,2005,11(11):1668-1672. 被引量:2
  • 2胡心传.119例鼻咽癌放疗后死于远处转移病例分析及放化研讨[J].肿瘤防治研究,1994,21(2):112-113. 被引量:6
  • 3Jun wan,Hong Li,Yuan Li,Mei-Ling Zhu,Po Zhao.Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients[J].World Journal of Gastroenterology,2006,12(7):1033-1037. 被引量:3
  • 4Vihinen PP, Hernberg M, Vuoristo MS, et al. A phase Ⅱ trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha 2a as first line treatment in metastatic melanoma[J]. Melanoma Res, 2010, 20(4):318-325.
  • 5di Pietro A, Ferrucci P, Munzone E, et al. Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTh)-naive advanced melanoma (MM) pa- tients (pts): a phase Ⅱ study [J]. J Clin Oncol, 2010, 28 (15s): Abstr 8536.
  • 6Del Vecchio M, Mortarini R, Canova S, et al. Bevacizumab plus fotemusine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of an- giogenesis and lymphangiogenesis factors [J]. Clin Cancer Res, 2010, Oct 28[Epub ahead of print].
  • 7Guo J, Si L, Kong Y, et al. A phase Ⅱ study of imatinib for advanced melanoma patients with KIT aberrations[J]. J Clin Oncol, 2010, 28(15s): Abstr 8527.
  • 8Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase Ⅲ study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma[J]. J Clin Oncol, 2000, 18(1):158-166.
  • 9Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase Ⅲ study[J]. J Clin Oncol, 2004, 22(6): 1118-1125.
  • 10Garbe C, Radny P, Linse R, et al. Adjuvant low-dose in- terferon α-2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase Ⅲ DeCOG trial in melanoma patients with regional lymph node metastasis[J]. Ann Oncol, 2008, 19(6): 1195-1201.

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部